

REPLY FAX

FAX: +49-(0)641 - 4996-77

ScheBo® • Biotech AG
Netanyastr. 3
35394 Gießen
Germany

Literature Service
Free-Of-Charge

Name:

Institute/company/hospital

Street

ZIP-code and City

Country

Phone Fax:

Email:

Please send us the following articles free of charge:

ScheBo® • Tumor M2-PK™ Stool Test

- Eigenbrodt, E.; Hardt, P.D.; Toepler, M.; Schlierbach, P.; Klör, H.U. (2003) **Tumor M2-PK: A new tool for metabolic profiling of gastrointestinal tumors**, Poster from the 31th Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), Edinburgh, UK, 30th August – 4th September, 2003
- Ewald, N.; Schaller, M.; Bayer, M.; Akinçi, A.; Bretzel, R.G.; Klör, H.U.; Hardt, P.D. (2007) **Fecal Pyruvate Kinase-M2 (Tumor M2-PK) Measurement: A New Screening Concept for Colorectal Cancer**, Anticancer Research 27: 1949-1952
- Hardt, P.D., Ngoumou, B., Rupp, J., Kloer, H.U. (2003) **Measurement of fecal Pyruvate Kinase Type M2 (Tumor M2-PK) Concentrations in Patients with Gastric Cancer, Colorectal Cancer, Colorectal Adenomas and Controls**, Anticancer Research 23: 851-854
- Hardt, P.D., Toepler, M., Ngoumou, B., Rupp, J., Kloer, H.U. (2003) **Fecal Pyruvate Kinase Concentrations (ELISA based on a Combination Of Clone 1 and Clone 3 Antibodies) For Gastric Cancer Screening**, Anticancer Research 23: 855-858
- Hardt, P.D.; Toepler, M.; Ngoumou, B.; Rupp, J.; Kloer, H.U. (2002) **Measurement of Fecal Pyruvate-Kinase Type M2 (Tumor M2-PK) Concentrations in Patients with Gastric Cancer, Colorectal Cancer, Colorectal Adenomas and Controls**, Poster of the 4th International Conference: Perspectives in Colorectal Cancer, Barcelona, Spain, 19. – 21. June, 2002
- Hardt, P.D.; Toepler, M.; Ngoumou, B.; Rupp, J.; Kloer, H.U. (2002) **Measurement of Fecal Pyruvate-Kinase Type M2 (Tumor M2-PK) Concentrations in Patients with Gastric Cancer, Colorectal Cancer, Colorectal Adenomas and Controls**, Poster from the 2nd Colorectal Cancer Conference, Rome, Italy, 24. - 25. October 2002
- Hardt, P.D.; Toepler, M.; Ngoumou, B.; Rupp, J.; Kröger, R.M.; Kloer, H.U. (2002) **Measurement of fecal tumor M2-PK concentrations in patients with gastrointestinal cancer**, Kongress für Laboratoriumsmedizin 2002, Düsseldorf, Germany, 18. - 20. November 2002
- Hardt, P.D.; Toepler, M.; Schlierbach, P.; Ngoumou, B.; Rupp, J.; Nalop, J.; Klör, H.U. (2003) **Messung der Tumor M2-Pyruvatkinase im Stuhl als Screening Marker für kolorektale Karzinome**, Beitrag zur 109. Jahrestagung der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, Germany, 26. – 30. April, 2003
- Hardt, P.D.; Mazurek, S.; Toepler, M.; Schlierbach, P.; Bretzel, R.G.; Eigenbrodt, E.; Kloer, H.U. (2004) **Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer**, British Journal of Cancer (2004) 91:, 980-984
- Hardt, P.D.; Schlierbach, P.; Toepler, M.; Bretzel, R.G.; Klör, H.U. (2004) **Tumor M2-PK in Stool: A Screening Tool for Colorectal Cancer**, Abstract from the World Congress on Gastrointestinal Cancer, Barcelona, Spain 16-19 June 2004

ScheBo® • Biotech AG

Netanyastr. 3 • 35494 Giessen • Germany

Phone: +49-(0)641-4996-0 • Fax: +49-(0)641-4996-77 • Internet: www.schebo.com

- Hardt, P.D.; Ewald, N.; (2008) **Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy**, *Expert Rev. Mol. Diagn.* 8(5):579-585
- Hardt, P.D.; Schlierbach, P.; Toepler, M.; Bretzel, R.G.; Kloer, H.U. (2005) **Faecal levels of Tumour M2-PK: sensitivity and specificity and correlation with tumour staging in colorectal cancer**, Poster from the NCRI Cancer Conference, Birmingham, UK, 2-5 October 2005
- Haug, U.; Rothenbacher, D.; Hardt, P.D.; Klör, H.U.; Stegmaier, Ch.; Brenner, H. (2004) **Tumor M2-PK Stool Test: A Promising Method for Colorectal Cancer Screening**, Abstract from the 26. Deutscher Krebskongress Berlin, Germany, 27.02.-01.03.2004
- Haug, U.; Rothenbacher, D.; Wente, M.N.; Seiler, C.M.; Stegmaier, C.; Breunner, H. (2007) **Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients**; *British Journal of Cancer – online publication – 3.* April 2007; doi: 10.1038/sj.bjc-6603712, www.bjcancer.com
- Koss, K.; Maxton, K.; Jankowski, J. (2005) **The Potential Use of Faecal Dimeric M2 Pyruvate Kinase (Tumour M2-PK) in Screening for Colorectal Cancer**, *Gut* 2(54):A20
- Koss, K.; Maxton, D.; Jankowski, J.A.Z. (2007) **Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention**, *Colorectal Disease* 10, 244-248
- Mazurek, S.; Hardt, P.D.; Toepler, M.; Schlierbach, P.; Bretzel, R.G.; Eigenbrodt, E.; Klör, H.U. (2003) **Tumor M2-PK Stool Test: A new tool for colorectal cancer screening**, Poster from the 2nd Biebrich Interdisciplinary Conference Colon and Rectal Cancer, Wiesbaden-Biebrich, Germany, 2. – 4. Oct. 2003
- McLoughlin, R.M.; Shiel, E.; Sebastian, S.S.; Ryan, B.; O'Connor, H.J.; Morain, C.O. (2005) **A new marker for colorectal cancer**, Beitrag zur Digestive Disease Week (DDW), Chicago, USA, 14.-19. May 2005
- Toepler, M.; Schlierbach, P.; Hardt, P.D.; Bretzel, R.G.; Klör, H.U. (2003) **Tumor M2-PK: A screening tool for colorectal cancer**, Poster from the 12. Hamburger Symposium on Tumor Markers, Hamburg, Germany, 30 November – 2 December 2003
- Toepler, M.; Schlierbach, P.; Hardt, P.D.; Bretzel, R.G.; Klör, H.U. (2004) **Tumor M2-PK Stool Test: A screening tool for colorectal cancer**, Poster from the 32nd Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), Helsinki, Finland, 19-23 June 2004
- Tonus, C.; Neupert, G.; Sellinger, M. (2006) **Colorectal Cancer Screening by the non-invasive Metabolic Biomarker Faecal Tumor M2-PK**, *World J Gastroenterol* 12(43): 7007-7011
- Tonus, C.; Neupert, G.; Witzel, K. (2009) **The faecal tumour M2-PK screening test for invasive & pre-invasive colorectal cancer: estimated specificity & results as a function of age for a study population of 4854 volunteers**, *NOWOTWORY Journal of Oncology* 59(2): 32e-37e

ScheBo® • Tumor M2-PK™ EDTA Plasma Test

- Brinck, U., Eigenbrodt, E., Oehmke, M., Mazurek, S., Fischer, G. (1994) **L- and M2- Pyruvate Kinase Expression in Renal Cell Carcinomas and their Metastases**, *Virch. Arch.*, 424: 177-185
- Cerwenka, H., Aigner, R., Bacher, H., Werkgartner, G., El-Shabrawi, A., Quehenberger, F., Mischinger, H.J. (1999) **TUM2-PK (Pyruvate Kinase Type Tumor M2), CA19-9 and CEA in Patients with Benign, Malignant and Metastasizing Pancreatic Lesions**, *Anticancer Research* 19: 849-852
- Christofk, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. (2008) **The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth**, *nature* 452:230-234
- Christofk, H.R.; Vander Heiden, M.G.; Wu, N.; Asara, J.M.; Cantley, L.C. (2008) **Pyruvate kinase M2 is a phosphotyrosine-binding protein**, *nature* 452:181-188
- Eigenbrodt, E., Basenau, D., Holthausen, S., Mazurek, S., Fischer, G. (1997) **Quantification of Tumor Type M2 Pyruvate Kinase (Tumor M2-PK) in Human Carcinomas**, *Anticancer Research*, 17: 3153-5156
- Eigenbrodt, E., Kallinowski, F., Ott, M., Mazurek, S., Vaupel, P. (1998) **Pyruvate Kinase and the Interaction of Amino Acid and Carbohydrate Metabolism in Solid Tumors**, *Anticancer Research* 18: 3267-3274
- Eigenbrodt, E., Mazurek, S., Friis, R.R. (1998) **Double role of pyruvate kinase type M₂ in the regulation of phosphometabolic pools**, in: *Cell Growth and Oncogenesis*, Bannasch, P., Kanduc, D., Papa, S., Trager, J.M. (eds), Birkhäuser Verlag, Basel, Switzerland

ScheBo® • Biotech AG

Netanyastr. 3 • 35494 Giessen • Germany

Phone: +49-(0)641-4996-0 • Fax: +49-(0)641-4996-77 • Internet: www.schebo.com

- Eigenbrodt, E., Reinacher, M., Scheefers-Borchel, U., Scheefers, H., Friis, R. (1992) **Double Role for Pyruvate Kinase Type M2 in Expansion of Phosphometabolite Pools Found in Tumor Cells**, *Critical Reviews in Oncogenesis* 3 (1,2): 91-115
- Elia, S.; Massoud, R.; Guggino, G.; Cristino, B.; Cortese, C.; De Massimi, A.R.; Zenobi, R. (2008) **Tumor type M2-pyruvate kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures**, *European Journal of Cardio-thoracic Surgery* 33: 723-727
- Fischer, G., Holzrichter, S., Reinacher, M., Heinrichs, M., Dembowski, J., Eigenbrodt, E. (1989) **Immunhistochemische Darstellung der L- und M2-Pyruvatkinase in primären Nierenzellkarzinomen und deren Metastasen**, *Verh. Dtsch. Ges. Path.* 73: 422 – 427
- Goonetilleke, K.S.; Mason, J.M.; Siriwardana, P.; King, N.K.; France, M.W.; Siriwardana, A.J. (2007) **Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary Cancer**, *Pancreas* 34: 318-324
- Hardt, P.D.; Ngoumou, B.K.; Rupp, J.; Schnell-Kretschmer, H.; Klör, H.U. (2000) **Tumor M2-Pyruvate Kinase: A Promising Tumor Marker in the Diagnosis of Gastro-intestinal Cancer**, *Anticancer Research*, 20: 4965-4968
- Hathurusinghe, H.R.; Goonetilleke, K.S.; Siriwardana, A.K. (2007) **Current Status of Tumor M2 Pyruvate Kinase (Tumor M2-PK) as a Biomarker of Gastrointestinal Malignancy**, *Annals of Surgical Oncology*, 14(10): 2714-2720
- Hoopmann, M., Warm, M., Mallmann, P., Thomas, A., Göhring U.-J., Schöndorf, Th. (2002) **Tumor M2 pyruvate kinase – determination in breast cancer patients receiving trastuzumab therapy**, *Cancer Letters* 187: 223 – 228, (2002)
- Hugo, F., Fischer, G., Eigenbrodt, E. (1999) **Quantitative Detection of Tumor M2-PK in Serum and Plasma**, *Anticancer Research*, 19: 2753-2758
- Hugo, F.; Mazurek, S.; Hardt, P.D.; Eigenbrodt, E. (2005) **Quantitative Detection of Tumor M2-PK: Evaluation of Blood and Stool Specimen Stability**, Poster from the 16th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine/FOCUS 2005 National Meeting of the Association of Clinical Biochemists, Glasgow, UK, 8.-12. May 2005
- Kaura, B.; Bagga, R.; Patel, F.D.; (2004) **Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma**; *J. Obstet. Gynaecol. Res.* Vol. 30, No. 3: 193-196
- Koss, K.; Harrison, R.F.; Gregory, J.; Darnton, S.J.; Anderson, M.R.; Jankowski, J.A.Z. (2004) **The metabolic marker tumor pyruvate kinase type M2 (tumor M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus**; *J Clin Pathol*, 57: 1156-1159
- Kumar, Y.; Tapuria, N.; Kirmani, N.; Davidson, B.R. (2007) **Tumour M2-pyruvate kinase: a gastrointestinal cancer marker**; *European Journal of Gastroenterology & Hepatology*, 19:265-276
- Kümmel, S.; Jeschke, S.; Landt, S.; Koriach, S.; Ulm, K.; Schmid, P.; Sehouli, J.; Blohmer, J.U.; Lichtenegger, W.; Thomas, A.(2006) **Tumor-specific correlation of tumor-type M2 pyruvate kinase (Tu M2-PK) in patients with cervical carcinoma**; Poster presented at the 2006 ASCO Annual Meeting, Atlanta, USA, June 2-6, 2006
- Lüftner, D.; Mesterharm, J.; Akrivakis, C.; Geppert, R.; Petrides, P.E.; Wernicke, K.-D.; Possinger, K. (2000) **Tumor Type M2 Pyruvate Kinase Expression in Advanced Breast Cancer**, *Anticancer Research*, 20: 5077-5082
- Lüftner, D.; Schweigert, M.; Geppert, R.; Possinger, K. (2001) **Tumor Type M2 Pyruvate Kinase in Colorectal Cancer: A Predictive Activity Marker versus Classical Mass Tumor Markers**, Abstract of the 3rd International Conference – Perspectives in Colorectal Cancer, Dublin, Ireland, June 7-9, 2001
- Lüftner, D.; Mazurek, S.; Henschke, P.; Mesterharm, J.; Schildhauer, S.; Geppert, R.; Wernecke, K.D.; Possinger, K.; (2003) **Plasma Levels of HER-2/neu, Tumor Type M2 Pyruvate Kinase and its Tyrosine-phosphorylated Metabolite in Advanced Breast Cancer**; *Anticancer Research* 23: 991-998
- Mazurek, S., Grimm, H., Wilker, S., Leib, S., Eigenbrodt, E. (1998) **Metabolic characteristics of different malignant cancer cells lines**, *Anticancer Research* 18: 3275-3282
- Mazurek, S.; Grimm, H.; Oehmke, M.; Weisse, G.; Teigelkamp, St.; Eigenbrodt, E.; (2000) **Tumor M2-PK and Glutaminolytic Enzymes in the Metabolic Shift of Tumor Cells**; *Anticancer Research*, 20: 5151-5154
- Mazurek, S.; Grimm, B.; Boschek, C.B.; Vaupel, P.; Eigenbrodt, E.; (2002) **Pyruvate kinase type M2 a crossroad in the tumor metabolome**; *British Journal of Nutrition* 87, Suppl. 1, 23-29
- Mazurek, S., Lüftner D., Wechsel, H.W., Schneider J., Eigenbrodt, E. (2002) **Tumor M2-PK: A Marker of the Tumor Metabolome, in: Tumor Markers: Physiology, Technology, and Clinical Applications**, Eleftherios, P. Diamandis et al. (Edts.) AACC Press 2002, 471-475
- Mazurek, S.; Scheefers-Borchel, U.; Scheefers, H.; Michel, A.; Basenau, D.; Fischer, G.; Dahlmann, N.; Laumen, R.; Eigenbrodt, E.; (1993) **Die Bedeutung der Pyruvatkinase in der Onkologie**, *nobatene medici*, 3: 97-104

- Mazurek, S.; Eigenbrodt, E.; (2003) **The Tumor Metabolome**; Anticancer Research 23: 1149-1154
- Mazurek, S.; Zwerschke, W.; Jansen-Dürr, P.; Eigenbrodt, E.; (2001) **Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7**; Oncogene 20, 6891-6898
- Mazurek, S.; Boschek, B.C.; Hugo, F.; Eigenbrodt, E. (2005) **Pyruvate kinase type M2 and its role in tumor growth and spreading**; Seminars in Cancer Biology 15:300-308
- Mazurek, S.; Drexler, H.C.A.; Troppmair, J.; Eigenbrodt, E.; Rapp, U.R. (2007) **Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism**; Anticancer Research 27: 3963-3972
- Mottet, N.; Dumollard, J.-M.; Gouzy-Grosjean, F.; Lucht-Versini, P.; Peoc'h, M.; Thibaudeau, E.; Rivière, M. (2007) **Expression Profiling of M2PK in 19 Different Human Tumor Types**; Poster presented at the 98th AACR, Los Angeles, USA, April 14-18 2007
- Oremek, G.M., Eigenbrodt, E., Rädle, J., Zeuzem, St., Seiffert, U.B. (1997) **Value of the Serum Levels of the Tumor Marker Tu M2-PK in Pancreatic Cancer**, Anticancer Research, 17: 3031-3034
- Oremek, G.M., Teigelkamp, S., Kramer, W., Eigenbrodt E., Usadel, K.-H. (1999) **The Pyruvate Kinase Isoenzyme Tumor M2 (Tumor M2-PK) as a Tumor Marker for Renal Carcinoma**, Anticancer Research, 19: 2599-2602
- Oremek, G.M., Sapoutzis, N., Kramer, W., Bickeböller, R., Jonas, D. (2000) **Value of Tumor M2 (Tu M2-PK) in Patients with Renal Carcinoma**, Anticancer Research 20: 5095-5098
- Oremek, G.M., Rutner, F.; Sapoutzis, N., Sauer-Eppel, H.; (2003) **Tumor Marker Pyruvate Kinase Type Tumor M2 in Patients Suffering from Diabetic Nephropathy**; Anticancer Research 23: 1155-1158
- Oremek, G.M., Müller, R.; Sapoutzis, N., Wigand, R.; (2003) **Pyruvate Kinase Type Tumor M2 Plasma Levels in Patients Afflicted with Rheumatic Diseases**; Anticancer Research 23: 1131-1134
- Presek, P., Reinacher, M., Eigenbrodt, E. (1988) **Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus**, FEBS Letters 242: 194 - 198
- Roigas, J., Schulze, G., Raytarowski, S., Jung, K., Schnorr D., Loening, S.A. (2001) **Tumor M2 Pyruvate Kinase in Plasma of Patients with Urological Tumors**, Tumor Biol 22: 282-285
- Scheefers-Borchel, U., Scheefers, H., Michel, A., Will, H., Fischer, G., Basenau, D., Dahlmann, N., Laumen, R., Mazurek, S., Eigenbrodt E. (1994) **Quantitative determination (ELISA) of pyruvatkinase type tumor M2, in: Current Tumor Diagnosis, Applications, Clinical Relevance**, Research-trends. R. Klapdor (ed.), W. Zuckschwerdt Verlag GmbH, München, Germany
- Schneider, J.; Morr, H.; Velcovsky, H.-G.; Weisse, G.; Eigenbrodt, E. (2000) **Quantitative Detection of Tumor M2-Pyruvate Kinase in Plasma of Patients with Lung Cancer in Comparison to Other Lung Diseases**; Cancer Detection and Prevention, 24(6): 531-535
- Schneider, J.; Neu, K.; Grimm, H.; Velcovsky, H.-G.; Weisse, G.; Eigenbrodt, E. (2002) **Tumor M2-Pyruvate Kinase in Lung Cancer Patients: Immunohistochemical Detection and Disease Monitoring**; Anticancer Research, 22: 311-318
- Schneider, J.; Neu, K.; Grimm, H.; Velcovsky, H.-G.; Morr, H.; Eigenbrodt, E. (2003) **Tumor M2-Pyruvate Kinase in the follow-up of inoperable lung cancer patients: a pilot study**; Cancer Letters 193: 91-98
- Schneider, J., Petri, G., Bitterlich, N., Philipp, M., Velcovsky, M.G., Morr, H., Katz, N., Eigenbrodt, E. (2003) **Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-lung cancer patients**, Clin Exp Med, in press
- Schneider, J.; Velcovsky, H.-G.; Morr, H.; Katz, N.; Neu, K.; Eigenbrodt, E. (2000) **Comparison of the Tumor Markers Tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the Diagnosis of Lung Cancer**; Anticancer Research, 20: 5053-5058
- Schneider, J., Peltri, G., Bitterlich, N., Neu, K.; Velcovsky, H.G., Morr, H., Katz, N., Eigenbrodt, E. (2003) **Fuzzy Logic-based Tumor Marker Profiles Including a New Marker Tumor M2-PK Improved Sensitivity of the Detection of Progression in Lung Cancer Patients**, Anticancer Research 23: 899-906
- Schneider, J.; Schulze, G.; (2003) **Comparison of the Tumor M2-Pyruvate Kinase (Tumor M2-PK), Carcinoembryonic Antigen (CEA), Carbohydrate Antigens CA 19-9 and CA 72-4 in the Diagnosis of Gastrointestinal Cancer**; Anticancer Research, 23: 5089-5094
- Schneider, J.; Bitterlich, N.; Schulze, G. (2005) **Improved Sensitivity in the Diagnosis of Gastro-intestinal Tumors by Fuzzy Logic-based Tumor Marker Profiles Including the Tumor M2-PK**; Anticancer Research 25: 1507-1516
- Schulze, G. (2000) **The Tumor Marker Tumor M2-PK: An Application in the Diagnosis of Gastrointestinal Cancer**; Anticancer Research, 20: 4961-4964
- Schulze, G. (2003) **HER-2/neu Gene Product in Serum – An Oncoprotein in the Diagnosis and Therapy of Breast Carcinoma**; Anticancer Research 23: 1007-1010

- Siriwardana HPP.; King, NKK.; France, MW.; Siriwardena, AK. (2005) **Prospective evaluation of the diagnostic accuracy of Plasma Tumour-M2-Pyruvate kinase (Tu-M2-PK) and serum carbohydrate antigen (CA 19-9) in pancreatic cancer**; Poster presented at the Digestive Disease Week (DDW), Chicago, USA, 14-19 May, 2005
- Siriwardena, A.; Siriwardana, P.; Mason, J.M.; Goonetilleke, K.; King, N.K.; France, M.W. (2006) **Tumour-M2-Pyruvate Kinase (Tu-M2-PK): A Novel Biomarker of Adverse Prognosis in Pancreatic Cancer**; Poster presented at the Digestive Disease Week (DDW), Los Angeles, USA, 20-25 May, 2006
- Steinberg, P. Klingelhöffer, A., Schäfer, A., Wüst, G., Weiße, G., Oesch, F., Eigenbrodt, E. (1999) **Expression of pyruvate kinase M₂ in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats**, *Vierchows Arch* 434: 213-220
- Ugurel, S.; Bell, N.; Sucker, A.; Zimpfer, A.; Rittgen, W.; Schadendorf, D. (2005) **Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma**; *Int. J. Cancer*: 117: 825-830
- Wechsel, H.W., Feil, G., Lahme, S., Loeser, W., Bichler, K.H. (1999) **Die plasmainaktive Form der Pyruvatkinase (pTuM2Pk) beim Nierenzellkarzinom: ein geeigneter Tumormarker ?**, *Akt. Urol.* 30: 249-253
- Wechsel, H.W., Petri, E., Bichler, K.-H., Feil G. (1999) **Marker for Renal Cell Carcinoma (RCC): The Dimeric Form of Pyruvate Kinase Type M2 (Tumor M2-PK)**, *Anticancer Research*, 19: 2583-2590
- Wechsel, H.W., Petri, E., Feil G., Nelde, H.-J., Bichler, K.-H., (1999) **Nierenzellkarzinom – Immunhistologische Untersuchung zur Expression der inaktiven Form der Pyruvatkinase**, *Der Urologe (A)* 6: 583-585
- Wechsel, H.W., Petri, E., Feil, G., Bichler, K.-H. (1997) **Tumor Specific Pyruvate Kinase (Tumor M2-PK): A potential marker for renal cell carcinoma (RCC) !**, *J Urology* 157: 424
- Zhang, B.; Chen, J.-Y.; Chen, D.D.; Wang, G.B.; Shen, P.; (2004) **Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls**; *World J Gastroenterol*, 10(11): 1643-1646